Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases
First Claim
Patent Images
1. A method of treating cardiovascular disease or muscle atrophy in a mammal comprising:
- (a) identifying a subject having a cardiovascular disease or muscle atrophy; and
(b) administering to said subject a modulator of a 5-HT2 receptor.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides for methods of treating and preventing muscle atrophy, cardiac hypertrophy, heart failure and/or primary pulmonary hypertension linked to a family of serotonin receptors called 5-HT2 receptors. The present invention further demonstrates that modulators of 5-HT2 receptors can inhibit or treat muscle atrophy, heart failure, cardiac hypertrophy, and/or primary pulmonary hypertension.
-
Citations
64 Claims
-
1. A method of treating cardiovascular disease or muscle atrophy in a mammal comprising:
-
(a) identifying a subject having a cardiovascular disease or muscle atrophy; and
(b) administering to said subject a modulator of a 5-HT2 receptor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 35)
-
-
27. A method of preventing muscle atrophy, cardiac hypertrophy, primary pulmonary hypertension, or heart failure comprising:
-
(a) identifying a patient at risk for muscle atrophy, cardiac hypertrophy, primary pulmonary hypertension, or heart failure; and
(b) administering to said patient a modulator of a 5-HT2 receptor. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 36, 37)
-
-
38. A method of identifying an inhibitor of muscle atrophy, heart failure, primary pulmonary hypertension, or hypertrophy in a mammal comprising:
-
(a) providing a 5-HT2 receptor modulator;
(b) treating a mammalian myocyte with said 5-HT2 receptor inhibitor; and
(c) measuring the expression of one or more muscle atrophy, cardiac hypertrophy, heart failure, or primary pulmonary hypertension parameters, wherein a change in said one or more muscle atrophy, cardiac hypertrophy, heart failure, or primary pulmonary hypertension parameters, as compared to one or more said parameters in a myocyte not treated with said 5-HT2 receptor modulator, identifies said 5-HT2 receptor modulator as an inhibitor of muscle atrophy, heart failure, cardiac hypertrophy, or primary pulmonary hypertension. - View Dependent Claims (39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)
-
-
57. A method of identifying an inhibitor of muscle atrophy, heart failure, primary pulmonary hypertension, or hypertrophy in a mammal comprising:
-
(a) providing a cell expressing an 5-HT2 receptor;
(b) contacting said 5-HT2 receptor inhibitor with a candidate inhibitor substance; and
(c) measuring the effect of the candidate inhibitor substance on the activity or expression of said 5-HT2 receptor, wherein a decrease in 5-HT2 activity, as compared to 5-HT2 activity in the absence of said candidate inhibitor substance, identifies said candidate inhibitor substance as an inhibitor of muscle atrophy, heart failure, cardiac hypertrophy or primary pulmonary hypertension. - View Dependent Claims (58, 59, 60, 61, 62, 63, 64)
-
Specification